Compare Cytokinetics Inc (CYTK) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Innovative Industrial Properties Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Innovative Industrial Properties Inc trades at $51.83 (market cap $1.43B). The key difference: Cytokinetics Inc is far larger — about 6× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 14.64% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Innovative Industrial Properties Inc for 86 Days on average.
| CYTK | IIPR | |
|---|---|---|
Market Cap | $8.62B | $1.43B |
Volume | 2,594,626 | 394,222 |
Sector | Health | Real Estate |
52-Week High | $87.26 | $64.67 |
52-Week Low | $54.76 | $44.58 |
Typical Hold Time | 19 Days | 86 Days |
Enterprise Value | $8.72B | $1.96B |
Dividend Yield | — | 14.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
IIPR trades at $51.92, up 1.35% with bearish technical signals but attractive valuation metrics including P/E of 11.75 and P/B of 0.83. The REIT reported mixed Q2 2026 earnings, beating expectations with $1.36 EPS versus $1.02 expected, while revenue declined to $266M in 2025. Recent news highlights a $245M mezzanine loan commitment and a $1.90 quarterly dividend, though cash flow turned negative in 2025.
The stock presents a high-yield opportunity with 13%+ dividend yield but faces tenant default risks and sector volatility. Analyst consensus is mixed with 36% buy ratings and $84.67 price target suggesting 63% upside, though technical indicators remain bearish. Regulatory catalysts and balance sheet strength provide potential upside amid cannabis REIT sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
